About Northwest Biotherapeutics (NASDAQ:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:NWBO
- CUSIP: N/A
- Web: www.nwbio.com
- Market Cap: $48.27 million
- Outstanding Shares: 186,061,000
- 50 Day Moving Avg: $0.18
- 200 Day Moving Avg: $0.19
- 52 Week Range: $0.14 - $0.98
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.10
- P/E Growth: 0.000
- Annual Revenue: $386,000.00
- Price / Sales: 78.81
- Book Value: ($0.15) per share
- Price / Book: -1.10
- EBITDA: ($69,120,000.00)
- Net Margins: -11,651.14%
- Return on Assets: -85.95%
- Current Ratio: 0.04%
- Quick Ratio: 0.04%
- Average Volume: 1.68 million shs.
- Beta: 1.75
- Short Ratio: 13.54
Frequently Asked Questions for Northwest Biotherapeutics (NASDAQ:NWBO)
What is Northwest Biotherapeutics' stock symbol?
Northwest Biotherapeutics trades on the NASDAQ under the ticker symbol "NWBO."
How were Northwest Biotherapeutics' earnings last quarter?
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.22. The firm had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.20 million. View Northwest Biotherapeutics' Earnings History.
Where is Northwest Biotherapeutics' stock going? Where will Northwest Biotherapeutics' stock price be in 2017?
0 brokers have issued 12 month price targets for Northwest Biotherapeutics' shares. Their predictions range from $0.61 to $0.61. On average, they anticipate Northwest Biotherapeutics' stock price to reach $0.61 in the next twelve months. View Analyst Ratings for Northwest Biotherapeutics.
Who are some of Northwest Biotherapeutics' key competitors?
Some companies that are related to Northwest Biotherapeutics include ContraFect Corporation (CFRX), Trillium Therapeutics (TRIL), Concordia International Corp (CXR), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON), Windtree Therapeutics (WINT), Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND) and Durata Therapeutics (DRTX).
Who are Northwest Biotherapeutics' key executives?
Northwest Biotherapeutics' management team includes the folowing people:
- Linda F. Powers, Chairperson of the Board, President, Chief Executive Officer
- Leslie J. Goldman, Senior Vice President - Business Development
- Anthony E. Maida Ph.D., Senior Vice President - Clinical Research
- Marnix L. Bosch Ph.D, Chief Technical Officer
- Alton L. Boynton Ph.D., Chief Scientific Officer, Director
- Susan B. Bayh, Independent Director
- Cofer Black, Independent Director
- Robert A. Farmer, Independent Director
- Jerry J. Jasinowski, Independent Director
- Navid Malik, Independent Director
How do I buy Northwest Biotherapeutics stock?
Shares of Northwest Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Northwest Biotherapeutics' stock price today?
MarketBeat Community Rating for Northwest Biotherapeutics (NASDAQ NWBO)MarketBeat's community ratings are surveys of what our community members think about Northwest Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Northwest Biotherapeutics stock can currently be purchased for approximately $0.16.
Consensus Ratings for Northwest Biotherapeutics (NASDAQ:NWBO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||$0.61 (273.09% upside)|Consensus Price Target History for Northwest Biotherapeutics (NASDAQ:NWBO)
Analysts' Ratings History for Northwest Biotherapeutics (NASDAQ:NWBO)
(Data available from 10/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|12/15/2016||S&P Equity Research||Lower Price Target||$0.73 -> $0.61||N/A|
Earnings History for Northwest Biotherapeutics (NASDAQ:NWBO)Earnings History by Quarter for Northwest Biotherapeutics (NASDAQ NWBO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/10/2015||Q2 2015||($0.32)||($0.54)||$0.20 million||$0.39 million||View||N/A|
|5/15/2014||Q1 2014||($0.33)||($0.46)||$0.20 million||View||N/A|
Earnings Estimates for Northwest Biotherapeutics (NASDAQ:NWBO)
Current Year EPS Consensus Estimate: $-1.8500 EPS
Next Year EPS Consensus Estimate: $-1.6000 EPS
Dividend History for Northwest Biotherapeutics (NASDAQ:NWBO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Northwest Biotherapeutics (NASDAQ:NWBO)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Northwest Biotherapeutics (NASDAQ:NWBO)
Latest Headlines for Northwest Biotherapeutics (NASDAQ:NWBO)
|NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm|
finance.yahoo.com - October 18 at 7:48 AM
|NW BIO Announces Registered Direct Offering Of $1.75 Million|
finance.yahoo.com - September 22 at 12:00 PM
|ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017|
finance.yahoo.com - September 6 at 7:05 AM
|DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference|
finance.yahoo.com - September 2 at 6:57 AM
|Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017|
finance.yahoo.com - August 25 at 9:29 AM
|Northwest Biotherapeutics: Statistically Satisfying - Seeking Alpha|
seekingalpha.com - August 24 at 10:22 AM
|Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ...|
www.nasdaq.com - May 23 at 6:29 PM
|Novocure Glioblastoma Drug Offers Survival Benefits|
www.investopedia.com - April 3 at 6:17 PM
|Biotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma|
www.bizjournals.com - March 31 at 9:08 AM
|Northwest closes $7.5M capital raise - Seeking Alpha|
seekingalpha.com - March 24 at 11:52 PM
|NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an|
biz.yahoo.com - March 23 at 7:28 PM
|NW BIO Announces Registered Direct Offering Of $7.5 Million|
us.rd.yahoo.com - March 17 at 7:06 PM
|Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash|
www.thestreet.com - March 16 at 7:40 PM
|BRIEF-NW Bio reaches agreement with convertible note holders|
www.reuters.com - March 10 at 8:41 PM
|8:16 am Northwest Biotherapeutics signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors, holder of $11 mln of the co's convertible senior notes|
us.rd.yahoo.com - March 10 at 8:41 PM
|NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi|
biz.yahoo.com - March 7 at 6:47 PM
|Biotech Stocks under Scanner -- ACADIA Pharma, Clovis Oncology, Galena Biopharma, and Northwest Biotherapeutics|
www.bizjournals.com - February 21 at 5:56 PM
|FDA lifts hold on Northwest Bio’s brain cancer immunotherapy trial|
www.bizjournals.com - February 9 at 8:01 PM
|Northwest Bio Spikes on Lifting of Clinical Hold (NWBO)|
www.investopedia.com - February 7 at 9:32 PM
|FDA Lifts Hold on Northwest Bio Cancer Drug Trial|
www.investopedia.com - February 7 at 4:30 PM
|BRIEF-NW bio announces lifting of clinical hold on DCVax -l phase III trial by FDA|
www.reuters.com - February 6 at 7:01 PM
|Flu Case Grinds Small Biotech to a Halt|
blogs.wsj.com - January 23 at 7:17 PM
|NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure|
biz.yahoo.com - January 23 at 9:49 AM
Northwest Biotherapeutics (NWBO) Chart for Friday, October, 20, 2017